Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$196,325Cash on Hand
0.2mo Cash Runway
Follow PCSA by emailGet an email when PCSA reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about PCSA, unsubscribe in one click. Privacy
📣 What PCSA Says Is Next
second half of 2029 · “A Clear Execution Roadmap The July financing generated approximately $183.3 million in net proceeds and is expected to fund operations into the second half of 2029, including support for the previously disclosed Phase 2 proof-of-concept development plan across the three indications we are initially pursuing: food allergy, CSU and relapsing MS.”
Company press release, Nov 5, 2026 · SEC filing
in 2027 · “With Phase 1 complete, the company intends to advance all three programs toward Phase 2 proof-of-concept studies, with initial data expected in 2027 and 2028.”
Company press release, Jul 29, 2026 · SEC filing
second half of 2026 · “Processa expects to initiate Phase 2 studies in food allergy and CSU in the second half of 2026, and in RMS in the first half of 2027, with multiple anticipated clinical milestones across the pipeline expected over the next 12–24 months.”
Company press release, Jul 29, 2026 · SEC filing
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 5, 2026 ·
Shareholder vote Processa sent stockholders a letter on its July Vidya Therapeutics acquisition and roughly $200 million private placement, which it says funds operations into the second half of 2029. Form 8-K · SEC filing · Press release
Nov 4, 2026 ·
Leadership Processa appointed Gregory J. Flesher as Chief Operating Officer effective November 4, 2026, at a $700,000 base salary and a target bonus up to 60%, with an option grant of 3.0% of fully-diluted capital contingent on stockholder approval of a 2027 equity plan. Form 8-K · SEC filing · Press release
Oct 29, 2026 ·
Leadership Justin Yorke resigned as board chair on October 27, 2026, and Dr. Sheila Gujrathi was appointed non-employee Executive Chair effective immediately, with Yorke remaining a board member. The company also announced FDA IND clearance for a Phase 2 CSU study of VT-7208 and a Generian research collaboration. Form 8-K · SEC filing · Press release
Oct 22, 2026 ·
Shareholder vote Processa is holding a virtual special meeting on Nov 30, 2026 to vote on a reverse stock split at a 1-for-3 to 1-for-9 ratio and on adjournment, following the July 28, 2026 Vidya merger and a roughly $200 million preferred stock private placement. The board recommends voting FOR both proposals. Form DEF 14A · SEC filing
Oct 5, 2026 ·
Deal Following the July 28, 2026 acquisition of Vidya Therapeutics, this amendment adds Vidya's audited 2025 and 2024 financials, unaudited 2026 interim financials, and pro forma combined financials, along with business and risk factor sections describing lead asset VT7208, a BTK inhibitor. Form 8-K/A · SEC filing · Press release
Aug 14, 2026 ·
Quarterly report for the period ended Jun 30, 2026 Form 10-Q · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Jun 2024 · Phase 1 · Results Expected · A Study of the Safety and PK of PCS6422 (Eniluracil) with Capecitabine in Patients with Advanced, Refractory GI Tract Tumors Registry primary completion date, not a results date
Sep 2022 · Phase 2 · Results Expected · Safety, PK and Efficacy of PCS12852 on Gastric Emptying Rate in Patients With Moderate to Severe Gastroparesis Registry primary completion date, not a results date
Feb 2020 · Phase 2 · Results Expected · A Study to Evaluate the Safety and Tolerability of PCS499 for the Treatment of Necrobiosis Lipoidica Registry primary completion date, not a results date
Oct 2019 · Phase 1/2 · Results Expected · RX-3117 in Combination With Abraxane® in Subjects With Metastatic Pancreatic Cancer Registry primary completion date, not a results date
Jul 2019 · Phase 1/2 · Results Expected · Dose-Finding and Safety Study for Oral Single-Agent to Treat Advanced Malignancies Registry primary completion date, not a results date
Jun 2018 · Phase 1 · Results Expected · Study to Evaluate the PK of Single and Optional Multiple Dosing Regimens of MR Formulations of PCS499 Compared to Trental® Administered to Healthy Subjects Registry primary completion date, not a results date
Also used in these trials (approved or third-party drugs, not PCSA's own candidates): Capecitabine.
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
PCSA holds $196,325 in cash and short-term investments (as of Jun 30, 2026) and burns about $2.8M/quarter from operations,
an estimated runway of 0.2 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure:80 · High
Cash runway 0 months +40
ATM program on file since Jul 2025 +15
Shelf registration (S-3, May 2024) +10
Going-concern doubt in the latest 10-Q +15Accordingly, we concluded that substantial doubt about our ability to continue as a going concern continues to exist within one year after the date these financial statements are available to be issued.10-Q, Nov 2026
Share count 2,798,241 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full PCSA picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for PCSA and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.